Cogent Biosciences Announces FDA Meeting And Alignment On MS2D2 Evaluating Bezuclastinib In Nonadvanced Systemic Mastocytosis Patients
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences has announced alignment with the FDA on the use of its novel patient-reported outcome measure, MS2D2, in the SUMMIT trial for evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis patients.
June 27, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cogent Biosciences has reached an agreement with the FDA on the use of MS2D2 in the SUMMIT trial for bezuclastinib in Nonadvanced Systemic Mastocytosis patients.
The alignment with the FDA on the use of MS2D2 in the SUMMIT trial is a significant regulatory milestone for Cogent Biosciences. This could positively impact investor sentiment and the stock price in the short term as it indicates progress in their clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100